Core Viewpoint - PharmaBlock's subsidiary, Jiangsu Aikang Technology Co., Ltd. (Aikang), successfully listed on the Hong Kong Stock Exchange, marking a new phase in its capital market journey [1][3]. Company Overview - Aikang is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiometabolic diseases [3][5]. - The company has established a pipeline of six clinical-stage candidates and one preclinical candidate, aiming to address significant unmet clinical needs globally [3][5]. Key Product Information - Aikang's core product, Tinengotinib (TT-00420), is a unique multi-target kinase inhibitor currently in pivotal clinical trials for cholangiocarcinoma (CCA) patients who have progressed after FGFR inhibitor treatment [4]. - Tinengotinib is also being explored for use in treating metastatic castration-resistant prostate cancer (mCRPC), breast cancer (BC), biliary tract cancers (BTC), and pan-FGFR solid tumors, with Phase II clinical studies completed for these indications [4]. Market Engagement - The company's IPO attracted significant attention from the capital market, bringing in several cornerstone investors, including Jiangbei Pharmaceutical and Kangfang Biotech [3]. - Aikang aims to leverage its listing as a catalyst to accelerate its global commercialization efforts and deliver breakthrough treatment options for patients [3][5].
「守正谦冲立基业，青囊致远启新程」药捷安康登陆港交所，加速全球商业化
Xin Lang Cai Jing·2025-06-23 08:34